Developer docs
API playgroundTry for free, no card

Search company profiles

Antibody Analytics

Full company profile

uuid000hvhv

Namestring
Antibody Analytics
Legal namestring
RoukenBio
Company typeenum
Private
Founded yearint
2015
Descriptiontext

RoukenBio (formerly Antibody Analytics) is a Glasgow-based preclinical contract research organization founded in 2015 that provides immunology-focused drug development services to global biotechnology and pharmaceutical clients. The company operates a discovery CRO model covering the full spectrum from early drug discovery through pre-IND testing, with particular depth in therapeutic antibody development, cell therapy approaches (including ex-vivo and in-vivo solid tumor work), and immune cell-based functional assays. Its core service offering spans three solution pillars: phase-based support across the drug development lifecycle, therapeutic modality expertise (small molecule, large molecule, and advanced therapeutics), and therapeutic-area specialization.

Short descriptiontext

RoukenBio (formerly Antibody Analytics) is a Glasgow-based preclinical immunology CRO providing antibody, cell therapy, and immune cell assay services to global biotech clients across 25 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGlasgow, United Kingdom
HQ citystring
Glasgow
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical immunology services, antibody functional assays, cell-based bioassays, immune cell assays, drug discovery CRO
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Discovery CRO providing drug development services to support global customer base in developing small molecule, large molecule and advanced therapeutics from early discovery through clinical phases. Services are project-based and collaborative research engagements.

rouken.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1RoukenCells
Description

Cellular tools including assay-ready index-2 cell lines, reporter cells and immune cell banks for modern therapeutic development.

rouken.bio
Core offering1 text field

Antibody Analytics (now operating as RoukenBio) is a preclinical contract research organisation (CRO) specialised in immunology, providing drug development services to biotechnology companies from early discovery through pre-IND testing. The company delivers ex vivo primary cell assays, immune cell-based functional assays, and bespoke assay design across small molecules, large molecules, and advanced therapeutics including antibody therapeutics and cell therapies. Its RoukenCells sub-brand offers assay-ready INDEX-2 cell lines, reporter cells, and immune cell banks as standalone cellular tools for modern therapeutic development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Net Promoter Score of 79 - clients highly value working with RoukenBio
+4 more records
Product overview1 text field

RoukenBio is a discovery Contract Research Organisation (CRO) offering a unified platform of preclinical immunology services. The company provides an integrated portfolio spanning Phase support (early discovery through clinical phases), therapeutic modality development services, and specialized assay capabilities. The RoukenCells sub-brand provides proven cellular tools including assay-ready cell lines, reporter cells, and immune cell banks. The overall offering combines assay development, service areas, scientific resources (whitepapers, research posters, webinars), and state-of-the-art equipment to support drug discovery from early phases through pre-IND testing.

Product and service2 records
1RoukenCells
CategoryCellular Reagents / Research Tools
Description

Assay-ready cellular tools including INDEX-2 cell lines, reporter cells, and immune cell banks designed for modern therapeutic development and offered to researchers developing biotherapeutics.

2Preclinical Immunology CRO Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

RoukenBio and AVS Bio formed a strategic partnership to strengthen therapeutic antibody development through integrated functional biology and discovery expertise. This partnership combines RoukenBio's immunology assay capabilities with AVS Bio's discovery expertise to provide comprehensive support for therapeutic antibody development programs.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based specialist immunology CRO offering immune monitoring, antibody characterization, and cell-based assays. Closely comparable in being a niche immunology-focused CRO supporting therapeutic antibody and biologics development.

TypeEmerging player
Description

Antibody discovery platform combining single-cell screening with downstream functional characterization. Tangentially competes where clients choose integrated antibody discovery plus functional evaluation, encroaching on the niche assay work RoukenBio performs.

TypeBroad incumbent
Description

Global CRO with significant discovery and safety assessment services including immunology and biologics capabilities. Competes for large-molecule preclinical programs and represents the incumbent scale alternative to specialist players like RoukenBio.

TypeBroad incumbent
Description

Diversified CRO and central laboratory services provider with extensive preclinical and clinical assay capabilities. Overlaps with RoukenBio in cell-based immunology and antibody characterization work delivered through an integrated, global platform.

TypeBroad incumbent
Description

Global life sciences services company offering antibody development, cell therapy, and biologics discovery services. Comparable in the cell-therapy and antibody functional assay segments addressed by RoukenBio, at a significantly larger global scale.

TypeDirect peer
Description

Specialty immunology and histopathology-focused CRO supporting immuno-oncology and cell therapy development. Direct peer in delivering complex immune cell-based assays and biomarker work to biotech and pharma preclinical pipelines.

TypeBroad incumbent
Description

Discovery services arm of Eurofins offering preclinical assay, pharmacology, and immunology capabilities across small and large molecules. Overlaps directly with RoukenBio in antibody and immune cell-based functional assays, but as part of a much broader service portfolio.

TypeDirect peer
Description

Specialized preclinical CRO offering a broad catalog of biology and immunology assays, including antibody and cell-based services for therapeutic discovery. Comparable in scale and positioning as a specialist supporting biotech preclinical workflows.

TypeEmerging player
Description

Technology-enabled preclinical discovery CRO offering automated assay services for small molecule and biologics programs. Emerging competitor for outsourced preclinical work where clients weigh specialist scientific depth versus platform-driven throughput.

TypeOthers
Description

Reagent and assay kit provider including immune cell lines, cytokines, and assay reagents. Adjacent via the RoukenCells-style reagent opportunity and as a supplier/adjacent ecosystem participant in antibody and immunology workflows.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Antibody Analytics

Preclinical Contract Research Servicesantibodyanalytics.com

RoukenBio (formerly Antibody Analytics) is a Glasgow-based preclinical immunology CRO providing antibody, cell therapy, and immune cell assay services to global biotech clients across 25 countries.

What Antibody Analytics does

RoukenBio (formerly Antibody Analytics) is a Glasgow-based preclinical contract research organization founded in 2015 that provides immunology-focused drug development services to global biotechnology and pharmaceutical clients. The company operates a discovery CRO model covering the full spectrum from early drug discovery through pre-IND testing, with particular depth in therapeutic antibody development, cell therapy approaches (including ex-vivo and in-vivo solid tumor work), and immune cell-based functional assays. Its core service offering spans three solution pillars: phase-based support across the drug development lifecycle, therapeutic modality expertise (small molecule, large molecule, and advanced therapeutics), and therapeutic-area specialization.

Antibody Analytics firmographics

Firmographics
Name
Antibody Analytics
Legal name
RoukenBio
Website
https://antibodyanalytics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
RoukenBio (formerly Antibody Analytics) is a Glasgow-based preclinical immunology CRO providing antibody, cell therapy, and immune cell assay services to global biotech clients across 25 countries.
Ownership category
akta.pro rank

Antibody Analytics industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Preclinical immunology services
  • Antibody functional assays
  • Cell-based bioassays
  • Immune cell assays
  • Drug discovery CRO

Where Antibody Analytics is headquartered

Location

Headquarters

HQ city
Glasgow
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Antibody Analytics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Discovery CRO providing drug development services to support global customer base in developing small molecule, large molecule and advanced therapeutics from early discovery through clinical phases. Services are project-based and collaborative research engagements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Antibody Analytics product offering

Product offering

Core offering

Antibody Analytics (now operating as RoukenBio) is a preclinical contract research organisation (CRO) specialised in immunology, providing drug development services to biotechnology companies from early discovery through pre-IND testing. The company delivers ex vivo primary cell assays, immune cell-based functional assays, and bespoke assay design across small molecules, large molecules, and advanced therapeutics including antibody therapeutics and cell therapies. Its RoukenCells sub-brand offers assay-ready INDEX-2 cell lines, reporter cells, and immune cell banks as standalone cellular tools for modern therapeutic development.

Product overview

RoukenBio is a discovery Contract Research Organisation (CRO) offering a unified platform of preclinical immunology services. The company provides an integrated portfolio spanning Phase support (early discovery through clinical phases), therapeutic modality development services, and specialized assay capabilities. The RoukenCells sub-brand provides proven cellular tools including assay-ready cell lines, reporter cells, and immune cell banks. The overall offering combines assay development, service areas, scientific resources (whitepapers, research posters, webinars), and state-of-the-art equipment to support drug discovery from early phases through pre-IND testing.

Differentiator

Problem solved

Functional benefit

Brands

  • RoukenCells: Cellular tools including assay-ready index-2 cell lines, reporter cells and immune cell banks for modern therapeutic development.

Products and services

  • RoukenCells Assay-ready cellular tools including INDEX-2 cell lines, reporter cells, and immune cell banks designed for modern therapeutic development and offered to researchers developing biotherapeutics.
  • Preclinical Immunology CRO Services

Quantifiable outcome

  • Net Promoter Score of 79 - clients highly value working with RoukenBio
  • +4 more outcomes

Companies that use Antibody Analytics

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Antibody Analytics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Antibody Analytics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AVS BiocoreStrategic or Co-development Partner · 17 February 2026RoukenBio and AVS Bio formed a strategic partnership to strengthen therapeutic antibody development through integrated functional biology and discovery expertise. This partnership combines RoukenBio's immunology assay capabilities with AVS Bio's discovery expertise to provide comprehensive support for therapeutic antibody development programs.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Antibody Analytics competitors and assessment

Company assessment

Direct peers

  • ProImmune: UK-based specialist immunology CRO offering immune monitoring, antibody characterization, and cell-based assays. Closely comparable in being a niche immunology-focused CRO supporting therapeutic antibody and biologics development.
  • CellCarta: Specialty immunology and histopathology-focused CRO supporting immuno-oncology and cell therapy development. Direct peer in delivering complex immune cell-based assays and biomarker work to biotech and pharma preclinical pipelines.
  • Reaction Biology: Specialized preclinical CRO offering a broad catalog of biology and immunology assays, including antibody and cell-based services for therapeutic discovery. Comparable in scale and positioning as a specialist supporting biotech preclinical workflows.

Emerging players

  • AbCellera: Antibody discovery platform combining single-cell screening with downstream functional characterization. Tangentially competes where clients choose integrated antibody discovery plus functional evaluation, encroaching on the niche assay work RoukenBio performs.
  • Arctoris: Technology-enabled preclinical discovery CRO offering automated assay services for small molecule and biologics programs. Emerging competitor for outsourced preclinical work where clients weigh specialist scientific depth versus platform-driven throughput.

Broad incumbents

  • Charles River Laboratories: Global CRO with significant discovery and safety assessment services including immunology and biologics capabilities. Competes for large-molecule preclinical programs and represents the incumbent scale alternative to specialist players like RoukenBio.
  • Labcorp (Covance): Diversified CRO and central laboratory services provider with extensive preclinical and clinical assay capabilities. Overlaps with RoukenBio in cell-based immunology and antibody characterization work delivered through an integrated, global platform.
  • GenScript: Global life sciences services company offering antibody development, cell therapy, and biologics discovery services. Comparable in the cell-therapy and antibody functional assay segments addressed by RoukenBio, at a significantly larger global scale.
  • Eurofins Discovery: Discovery services arm of Eurofins offering preclinical assay, pharmacology, and immunology capabilities across small and large molecules. Overlaps directly with RoukenBio in antibody and immune cell-based functional assays, but as part of a much broader service portfolio.

Others

  • Bio-Techne: Reagent and assay kit provider including immune cell lines, cytokines, and assay reagents. Adjacent via the RoukenCells-style reagent opportunity and as a supplier/adjacent ecosystem participant in antibody and immunology workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Antibody Analytics social profiles

Digital presence

Antibody Analytics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Antibody Analytics leadership team

Management profile

Number of profiles

Profiles1 record

Antibody Analytics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Antibody Analytics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antibody Analytics

What does Antibody Analytics do?

Antibody Analytics (now operating as RoukenBio) is a preclinical contract research organisation (CRO) specialised in immunology, providing drug development services to biotechnology companies from early discovery through pre-IND testing. The company delivers ex vivo primary cell assays, immune cell-based functional assays, and bespoke assay design across small molecules, large molecules, and advanced therapeutics including antibody therapeutics and cell therapies. Its RoukenCells sub-brand offers assay-ready INDEX-2 cell lines, reporter cells, and immune cell banks as standalone cellular tools for modern therapeutic development.

Is Antibody Analytics a public or private company?

Antibody Analytics is a private company. It is classified as private equity controlled and is currently operating.

When was Antibody Analytics founded?

Antibody Analytics was founded in 2015. It employs 51 to 100 people.

Where is Antibody Analytics based?

Antibody Analytics is headquartered in Glasgow, United Kingdom, in the Europe region.

How does Antibody Analytics make money?

One revenue line is on record: contract Research Services.

Who are Antibody Analytics's main competitors?

Direct peers on record are ProImmune, CellCarta and Reaction Biology. Emerging players are AbCellera and Arctoris. Broad incumbents are Charles River Laboratories, Labcorp (Covance), GenScript and Eurofins Discovery. Bio-Techne is listed as an others.

Does Antibody Analytics have an API?

No public API is recorded for Antibody Analytics.

What industry is Antibody Analytics in?

Antibody Analytics's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales